X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs LUPIN LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB LUPIN LTD DR. REDDYS LAB/
LUPIN LTD
 
P/E (TTM) x 28.9 27.0 107.0% View Chart
P/BV x 3.1 2.8 109.7% View Chart
Dividend Yield % 0.9 0.6 144.7%  

Financials

 DR. REDDYS LAB   LUPIN LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
LUPIN LTD
Mar-18
DR. REDDYS LAB/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,7881,465 190.3%   
Low Rs1,902727 261.5%   
Sales per share (Unadj.) Rs860.8349.6 246.2%  
Earnings per share (Unadj.) Rs57.15.6 1,026.8%  
Cash flow per share (Unadj.) Rs122.029.6 412.5%  
Dividends per share (Unadj.) Rs20.005.00 400.0%  
Dividend yield (eoy) %0.90.5 187.0%  
Book value per share (Unadj.) Rs757.7300.3 252.3%  
Shares outstanding (eoy) m165.91452.08 36.7%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x2.73.1 86.9%   
Avg P/E ratio x41.1197.2 20.8%  
P/CF ratio (eoy) x19.237.1 51.9%  
Price / Book Value ratio x3.13.6 84.8%  
Dividend payout %35.090.0 39.0%   
Avg Mkt Cap Rs m389,034495,502 78.5%   
No. of employees `00023.517.0 138.0%   
Total wages/salary Rs m32,14928,647 112.2%   
Avg. sales/employee Rs Th6,070.89,273.6 65.5%   
Avg. wages/employee Rs Th1,366.61,681.0 81.3%   
Avg. net profit/employee Rs Th402.5147.4 273.0%   
INCOME DATA
Net Sales Rs m142,810158,042 90.4%  
Other income Rs m1,5521,504 103.2%   
Total revenues Rs m144,362159,545 90.5%   
Gross profit Rs m23,51231,475 74.7%  
Depreciation Rs m10,77210,859 99.2%   
Interest Rs m7882,044 38.6%   
Profit before tax Rs m13,50420,076 67.3%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m34435 977.3%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m4,3802,885 151.8%   
Profit after tax Rs m9,4682,513 376.8%  
Gross profit margin %16.519.9 82.7%  
Effective tax rate %32.414.4 225.7%   
Net profit margin %6.61.6 417.0%  
BALANCE SHEET DATA
Current assets Rs m104,984122,095 86.0%   
Current liabilities Rs m68,93850,956 135.3%   
Net working cap to sales %25.245.0 56.1%  
Current ratio x1.52.4 63.6%  
Inventory Days Days7485 87.9%  
Debtors Days Days104120 86.4%  
Net fixed assets Rs m104,385129,876 80.4%   
Share capital Rs m830904 91.8%   
"Free" reserves Rs m124,886134,866 92.6%   
Net worth Rs m125,716135,771 92.6%   
Long term debt Rs m25,08964,245 39.1%   
Total assets Rs m225,443263,054 85.7%  
Interest coverage x18.110.8 167.6%   
Debt to equity ratio x0.20.5 42.2%  
Sales to assets ratio x0.60.6 105.4%   
Return on assets %4.51.7 262.7%  
Return on equity %7.51.9 407.0%  
Return on capital %9.73.7 260.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62353,141 136.7%   
Fx outflow Rs m18,91619,335 97.8%   
Net fx Rs m53,70733,807 158.9%   
CASH FLOW
From Operations Rs m18,03017,512 103.0%  
From Investments Rs m-14,883-14,073 105.8%  
From Financial Activity Rs m-4,440-14,921 29.8%  
Net Cashflow Rs m-1,236-11,482 10.8%  

Share Holding

Indian Promoters % 25.5 46.6 54.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 31.9 110.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.1 151.5%  
Shareholders   75,885 98,259 77.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets End Lower; Metal Stocks Top Losers(Closing)

Indian share markets settled lower today led by a fall in the financial stocks after the rupee hit a record low of 70.32 per dollar.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 16, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS